Results for the quarter and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medico Intercontinental Ltd reported standalone revenue of Rs 5,680.62 lakhs for FY2026, a decline of about 1.4% from Rs 5,763.75 lakhs in FY2025. Net profit after tax fell 14.9% to Rs 218.36 lakhs from Rs 256.58 lakhs previously. The company has 6 subsidiaries and 1 joint venture (Medico Lab) included in consolidated results. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements. A significant accounting policy change was implemented where the company switched from proportionate consolidation to equity method for its joint venture Medico Lab, resulting in restated comparative figures for the prior year. The internal auditor was changed from the previous firm to M/s MJV & Co for FY2026-27.
The decline in standalone revenue and profit may exert negative pressure on the stock price in the near term. The clean audit opinion and restatement of consolidated figures to reflect proper joint venture accounting provides transparency for investors, though the negative PAT and revenue decline are concerning signals for financial performance.